Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVRd in Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Dec 2023; status: recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06158269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158269.